ArticleCureus2026
Coexistence of Mycosis Fungoides and Hodgkin Lymphoma in a Pediatric Patient: A Report of a Rare Case.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycosis fungoides (MF) is the most common primary cutaneous T‑cell lymphoma, usually affecting adults aged 50-60 years; pediatric presentation is rare. We report a 12‑year‑old patient whose course spanned five years; skin lesions began at age 8, were misdiagnosed and treated as inflammatory dermatosis with topical steroids for four years. At age 12, B‑symptoms, lymphadenopathy and organomegaly led to the diagnosis of MF Stage IA (T1bNxM0B0) and synchronous Hodgkin lymphoma (HL) Stage IVB, with an Epstein-Barr virus (EBV) viral load of 2.5 log₁₀ copies/mL. Treatment with three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) + pembrolizumab due to drug availability, followed by six cycles of PC‑AVBE (prednisone, cyclophosphamide, doxorubicin, vincristine, bleomycin, and etoposide) and radiotherapy, achieving complete remission. This case highlights diagnostic challenges, immune dysregulation, and adapted treatment in resource‑limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.